How Might Anti-Obesity Medication Look Like in the Future?
Diabetes Insights - Breakthroughs and InnovatorsShow Notes
In this episode, leading experts Dr. Daniela Liśkiewicz and Dr. Juan Pablo Frías explore the rapidly evolving landscape of anti-obesity medications.
From the rise of GLP-1-based therapies and oral treatments to next-generation multi-agonists, this discussion highlights how innovation is transforming obesity care. The conversation moves beyond weight loss alone, focusing on treatment quality, long-term weight maintenance, and patient-centred outcomes.
The speakers also examine emerging therapeutic targets, the importance of preserving muscle mass, and the growing role of lifestyle interventions alongside pharmacotherapy. Looking ahead, they share insights into future directions, from resetting metabolic “set points” to improving global access to treatment.
More from Diabetes Insights - Breakthroughs and Innovators
How does exercise stimulate glucose uptake in muscle and what can this teach us about treating type 2 diabetes?
Prof. Anette-Gabriele Ziegler, this year’s Claude Bernard Prize Lecture recipient, reflects on her career in type 1 diabetes research and the evolution of our understanding of the disease.
The EASD’s first clinical practice guideline on the assessment and management of diabetes distress in adults living with type 1 or type 2 diabetes has now been published in Diabetologia.
How can people living with diabetes help shape the future of diabetes care?
In this episode, Dr Jeroen van der Velde explores one of the most common questions in lifestyle medicine: does the time of day you exercise make a difference?